Review highlights arterial spin-labeling MRI as a noninvasive biomarker for monitoring neurodegenerative disease, suggesting significant implications for treatment monitoring.
To review the current evidence supporting arterial spin-labeling MRI (ASL-MRI) as a cost-effective, noninvasive biomarker for monitoring neurodegenerative disease progression and treatment response, emphasizing its role as an alternative to FDG-PET and amyloid imaging.
No takes yet. Share an insight, caveat, or question.
Tello et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: